CORRESP

INTREXON CORPORATION

20374 Seneca Meadows Parkway

Germantown, Maryland 20876

Telephone: (301) 556-9900

April 19, 2018

VIA EDGAR

Mr. Joel Parker

Senior Assistant Chief Accountant

Office of Beverages, Apparel and Mining

Division of Corporation Finance

Securities and Exchange Commission

100 F Street, NE

Washington, DC 20549

 

Re: Intrexon Corporation
  Form 10-K for the Fiscal Year Ended December 31, 2017
  Filed March 1, 2018
  File Number 001-36042

Dear Mr. Parker:

We have reviewed the comments of the staff (the “Staff”) of the Securities and Exchange Commission, as set forth in its letter dated April 9, 2018, with respect to the above-referenced filing. Enclosed herewith are the Staff’s comments followed by responses on behalf of Intrexon Corporation (the “Company”).

Form 10-K for the Fiscal Year Ended December 31, 2017

Financial Statements

Consolidated Balance Sheets, page F-5

Comment:

 

  1. Please disclose your deferred revenue from related parties on the face of the balance sheet. Refer to Rule 4-08(k) of Regulation S-X.

Response:

The Company confirms that in future quarterly and annual filings, starting with the Company’s Form 10-Q for the period ended March 31, 2018 (the “March 31, 2018 10-Q”), it will disclose deferred revenue from related parties on the face of the balance sheet,


Mr. Joel Parker

April 19, 2018

Page 2 of 4

 

consistent with the Staff’s comment. Below, using the balance sheet at December 31, 2017 and 2016 disclosed in the Company’s Form 10-K for the fiscal year ended December 31, 2017 (the “2017 10-K”), is an illustrative example of the disclosure the Company will include in future filings (new language is underlined):

Intrexon Corporation and Subsidiaries

Consolidated Balance Sheets

December 31, 2017 and 2016

 

(Amounts in thousands, except share data)    2017     2016  

Liabilities and Total Equity

    

Current liabilities

    

Accounts payable

   $ 8,701     $ 8,478  

Accrued compensation and benefits

     6,474       6,540  

Other accrued liabilities

     21,080       15,776  

Deferred revenue, including $29,155 and $33,802 from related parties as of December 31, 2017 and 2016, respectively

     42,870       53,364  

Lines of credit

     233       820  

Current portion of long term debt

     502       386  

Deferred consideration

     —         8,801  

Related party payables

     313       440  
  

 

 

   

 

 

 

Total current liabilities

     80,173       94,605  

Long term debt, net of current portion

     7,535       7,562  

Deferred revenue, net of current portion, including $157,628 and $214,301 from related parties as of December 31, 2017 and 2016, respectively

     193,527       256,778  

Deferred tax liabilities, net

     15,620       17,007  

Other long term liabilities

     3,451       3,868  
  

 

 

   

 

 

 

Total liabilities

     300,306       379,820  
  

 

 

   

 

 

 

Commitments and contingencies (Note 17)

    

Total equity

    

Common stock, no par value, 200,000,000 shares authorized as of December 31, 2017 and 2016; and 122,087,040 shares and 118,688,770 shares issued and outstanding as of December 31, 2017 and 2016, respectively

     —         —    

Additional paid-in capital

     1,397,005       1,325,780  

Accumulated deficit

     (847,820     (729,341

Accumulated other comprehensive loss

     (15,554     (36,202
  

 

 

   

 

 

 

Total Intrexon shareholders’ equity

     533,631       560,237  

Noncontrolling interests

     12,914       9,011  
  

 

 

   

 

 

 

Total equity

     546,545       569,248  
  

 

 

   

 

 

 

Total liabilities and total equity

   $ 846,851     $ 949,068  
  

 

 

   

 

 

 


Mr. Joel Parker

April 19, 2018

Page 3 of 4

 

Notes to Consolidated Financial Statements

5. Collaboration and Licensing Revenue, page F-32

Comment:

 

  2. Please disclose the estimated remaining performance period for your significant collaboration agreements.

Response:

The Company confirms that in future quarterly and annual filings, starting with the March 31, 2018 Form 10-Q, it will disclose the estimated remaining performance period for its significant collaboration agreements, consistent with the Staff’s comment. Below, using disclosure from the 2017 10-K, is an illustrative example of the disclosure the Company will include in future filings (new language is underlined):

The following table summarizes the remaining balance of deferred revenue associated with upfront and milestone payments for each significant collaboration and licensing agreement as of December 31, 2017 and 2016, including the estimated, average remaining performance period as of December 31, 2017.

 

     Average Remaining
Performance Period (Years)
     December 31,  
        2017      2016  

ZIOPHARM Oncology, Inc.

     6.0      $ 90,496      $ 138,809  
  

 

 

       

Oragenics, Inc.

     6.4        6,719        7,766  
  

 

 

       

Fibrocell Science, Inc.

     6.9        16,607        19,026  
  

 

 

       

Genopaver, LLC

     6.3        1,704        1,977  
  

 

 

       

Intrexon Energy Partners, LLC

     6.3        15,625        18,125  
  

 

 

       

Persea Bio, LLC

     7.0        3,500        4,000  
  

 

 

       

Ares Trading S.A.

     6.4        40,789        47,178  
  

 

 

       

Intrexon Energy Partners II, LLC

     6.9        13,833        15,833  
  

 

 

       

Intrexon T1D Partners, LLC

     7.2        8,435        8,653  
  

 

 

       

Harvest start-up entities (1)

     7.4        18,400        20,208  
  

 

 

       

Other

     4.3        14,423        16,292  
  

 

 

    

 

 

    

 

 

 

Total

      $ 230,531      $ 297,867  
     

 

 

    

 

 

 

 

(1) As of December 31, 2017 and December 31, 2016, the balance of deferred revenue for collaborations with Harvest start-up entities includes Thrive Agrobiotics, Inc.; Exotech Bio, Inc.; Relieve Genetics, Inc.; AD Skincare, Inc.; Genten Therapeutics, Inc.; and CRS Bio, Inc.

*    *    *    *    *


Mr. Joel Parker

April 19, 2018

Page 4 of 4

 

If you have any questions concerning this letter or if you would like any additional information, please do not hesitate to call me at (301) 556-9900.

Very truly yours,

/s/ Rick L. Sterling

Rick L. Sterling

Chief Financial Officer

 

cc: Donald P. Lehr, Intrexon Corporation

Matthew Keffer, PricewaterhouseCoopers LLP

William I. Intner, Hogan Lovells US LLP